We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies from this website. If you would like to change your preferences you may do so by following these instructions.

OK

Macedonian Cultivation Facility Standardize on Heliospectra LED Technology

Medical Cannabis Grower Continue Expansion and invest in Heliospectra LED Lighting Solutions to Standardize Medicinal Profiles and Quality
(GOTHENBURG, Sweden/SAN FRANCISCO, CA, June 14, 2018 –
Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, announces a new order from Medical 420 DOO, a state-of-the-art medicinal cannabis facility in Macedonia. The grower is rapidly scaling production and continues to standardize on Heliospectra LED lighting solutions. The order is valued at around 3 728 000 SEK ($432,643 USD).

Heliospectra Elixia

“With Heliospectra we have been able to standardize our products to the highest quality while increasing yields. As the medical market is growing, our operations are expanding and we remain entirely committed to supplying our customers and patients with consistent medical products and effective treatments,” said Tony Gasovski, owner and founder of Medical 420.

The indoor controlled environment facility is currently equipped with Heliospectra Eos™ (formerly E60) series, the new order also implements Heliospectra’s intelligent Elixia™ (formerly LX60) series to add automation and continue to improve quality, accelerate harvest cycles and production cycles while delivering consistent yields.

“Medical 420 is achieving rapid, positive ROI with the simple, yet powerful Heliospectra solution,” said Ali Ahmadian, CEO of Heliospectra. He added, “We’re pleased to support the Medical 420 team in achieving consistently high-quality product profiles, harvest after harvest.”

The order will ship and be visible in the accounts during Q3 and Q4.